Needham Reiterates Hold on Sage Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics (NASDAQ:SAGE).
October 30, 2024 | 9:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics, indicating a neutral stance on the stock.
The reiteration of a Hold rating suggests that the analyst does not see significant upside or downside in the short term for Sage Therapeutics. This neutral stance is likely to result in minimal immediate impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100